Susan N. Vogt

Ms. Vogt joined the Board of Directors of Anika Therapeutics in October 2018. Ms. Vogt previously served as President and Chief Executive Officer of Aushon Biosystems, Inc., a developer of a multiplex immunoassay platform, from 2013 until the company was acquired by Quanterix Corporation in January 2018. From 2006 to 2011, Ms. Vogt was President and Chief Executive Officer of Seracare Life Sciences, Inc., a Nasdaq-listed life sciences developer of products facilitating human diagnostics and therapeutics. From 1981 to 2005, she served in various officer positions at Millipore Corporation (now part of MillaporeSigma, the life science business of Merck KGaA), an NYSE-listed developer of biotechnology and pharmaceutical drug therapies, including as President of the Biopharmaceutical Division, Vice President and General Manager of the Laboratory Water Division, Vice President and General Manager of the Analytical Products Division, Vice President and General Manager of the Analytical Division, and Finance Manager, Division Controller. Ms. Vogt received her M.B.A. from Boston University with a concentration in Finance and her B.A. from Brown University in Art History. Ms. Vogt’s qualifications for membership on the Board include more than thirty-five years of experience in the global life science research, pharmaceutical, biotech and clinical diagnostics industries, during which Ms. Vogt established a reputation for driving operational efficiency and productivity, successfully scaling commercial operations, enhancing profitability by streamlining, restructuring and consolidating operations, and delivering sustained revenue and cash flow growth at multiple companies. Ms. Vogt also has a deep understanding of finance and accounting as a result of holding financial-based roles during her career and serving on the audit committees of several private and public companies. Ms. Vogt serves as Chair on the Governance and Nominating Committee and as a designated financial expert member of the Audit Committee.